Novanta's Cash Flow Has Reappeared. The Stock Has Already Moved On It.

Novanta's old story ran like this: a medical and automation technology company whose growth decelerated from a 10.7% five-year CAGR down to roughly 7% annualized, and whose cash flow was thin enough that the market treated it like a multiple expansion bet rather than a cash-generation play.

That story is stale. Q2 organic revenue growth hit 9.3% — the strongest organic quarter since Q1 2023. Adjusted EBITDA grew 16% to a 16% increase in adjusted EBITDA on a 22.8% margin. But the number that actually changes the setup is free cash flow: $57.5 million in Q2, nearly five times the $11.7 million a year ago. Year-to-date operating cash flow is $116.5 million versus $46.8 million prior year. The cash engine is working again.

Management raised full-year 2026 guidance following the close of the Riverpoint Medical acquisition across the board. Revenue is now expected at $1.13–$1.14 billion (well above the $1.05 billion the market had penciled in). Adjusted EBITDA guidance jumped to $273–$278 million from roughly $248 million in consensus. Q3 guidance is the knockout: next quarter’s revenue guidance ($302 million at the midpoint) against a $263 million estimate. The midpoint implies 22% year-over-year growth next quarter.

The Riverpoint multiplier

None of this happens in isolation. Novanta completed the acquisition of Riverpoint Medical on July 27, roughly two weeks before the Q2 quarter-end. The deal — $1.2 billion upfront plus a $250 million milestone — was funded from a mix of cash on hand, the existing credit facility, and proceeds from a $300 million equity raise.

The strategic logic is clear. Riverpoint doubles Novanta's recurring medical consumables revenue to roughly $300 million annually. It pushes medical end-market exposure to 60% of total revenue. And Riverpoint is growing revenue and cash flow at roughly twice Novanta's historical pace, with a long-term growth outlook of 12–15%. The acquisition is immediately accretive to adjusted gross margins, EBITDA margins, and EPS. In 2027, Riverpoint should add $0.18–$0.25 to adjusted EPS in its first full year and generate roughly $80 million in adjusted EBITDA including synergies.

The valuation problem

Here's where the inflection narrative runs into the price. The stock is up 44% over the trailing twelve months and 39.8% year-to-date. It surged 16.7% over the five days following earnings. At $166, Novanta trades at 102 times trailing earnings, 122 times forward earnings, and 46 times EV/EBITDA. The price-to-free-cash-flow multiple stands at 47.

These are not numbers that leave room for a slow walk to the upside. The stock has already absorbed the recovery story, the guidance raise, and the Riverpoint accretion. The market isn't pricing the old story anymore — it's pricing the new one and asking whether it can keep accelerating.

The GAAP crack

One detail that matters: GAAP operating margin fell to 6.8% in Q2, down sharply from 11.4% a year ago. Management attributed this to operating expenses — marketing, R&D, and administrative overhead — growing faster than revenue. Gross margin held up at 47.1%. So the operating engine underneath is intact, but the company is spending aggressively to fuel the growth inflection. That's a choice, not a breakdown. But it means GAAP earnings per share of $0.30 in Q2 look thin next to the $0.89 adjusted figure.

The market rewards adjusted metrics when the operating trajectory is clear. It punishes them when expenses grow unrestrained. This is a near-term balance point.

What the setup requires

The thesis going forward has a specific financial bridge. Riverpoint closes the quarter, begins contributing to revenue and cash flow, and Novanta maintains the organic growth momentum that returned in Q2. Over the next twelve months, that combination should push full-year free cash flow toward the $200–$220 million range — roughly double the current TTM pace of $114 million.

At 47 times current free cash flow, Novanta is expensive by any traditional measure. But if next year's FCF runs toward $200 million and the market is willing to grant a 20–25x multiple on the new growth profile (a multiple that would still be below many medtech consumables names), the implied range is $175–$215. That's a 6–30% upside from current levels.

Simple forward multiples on the FCF bridge, not a DCF with terminal growth assumptions dressed up as precision.

Where it could break

The acquisition integration is the obvious execution risk. Riverpoint is accretive on paper — the question is whether Novanta's operating discipline transfers to a surgical consumables business with different margins and different customer dynamics. Management says synergies should run $80+ million over five years. If those take longer to realize, or if organic growth decelerates back toward the 7% that made the market skeptical in the first place, the multiple compression risk is real.

The other risk is the equity overhang. The $300 million raise used to fund the deal dilutes existing shareholders. That's a known quantity, but it caps the per-share upside unless operating cash flow and earnings growth comfortably outpace the dilution.

The invalidation condition is simpler than either of those: if Q3 misses the $300–$304 million revenue guide or if organic growth falls back below 7%, the rerating narrative fractures. At these multiples, missing guidance is not a setback — it's a thesis event.

The posture

Novanta is not a turnaround play anymore. It's a momentum name with a real operating inflection behind it. The cash flow has reappeared, the organic growth is back, and the Riverpoint addition gives it a higher-growth, higher-recurring revenue profile than the market priced two quarters ago.

But the stock has already moved. The entry is no longer about catching the inflection — it's about whether the next twelve months of execution justify a multiple that's already stretched. For holders, the setup remains intact as long as the cash flow trajectory holds and Riverpoint delivers. For new entries, the risk-reward is tighter. The financial bridge is explicit, but the margin for error at 122x forward earnings is thin.

Discipline over ego. If the next quarter confirms the bridge, the thesis strengthens. If it doesn't, the multiple tells you exactly how fast the market will vote.